differentiated thyroid carcinoma
Oncology · 2014–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cabozantinib Locally advanced or metastatic differentiated thyroid carcinoma (DTC) that is radioactive iodine (RAI) refractory or ineligible, with progressive disease… | Mar 2024 | Recommended with restriction | none received |
| cabozantinib Treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (DTC) who are… | Nov 2023 | Not recommended | input received Australian Thyroid Foundation |
| sorafenib Treatment of locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine. | Jul 2014 | Not recommended | 16 individuals |
Who spoke
Australian Thyroid Foundation
What the PBS pays
$56M in government benefit over 2024–25, across 6,029 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| cabozantinib | $55.8M |
| sorafenib | $0.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.